$13.970
-0.099 (-0.71%)At close
AMRN News
AMRN Events
Amarin Celebrates New Guidelines Including CV Risk Treatment for Hypertriglyceridemia Patients
Amarin celebrated the recommendation that the treatment of CV risk in patients with hypertriglyceridemia be part of a broader dyslipidemia management as discussed in the 2026 American College of Cardiology, or ACC, / American Heart Association, or AHA,/Multisociety Dyslipidemia Guideline Update. These newly-issued, evidenced-based recommendations summarize the clinical role of icosapent ethyl in reducing cardiovascular, or CV, risk in statin-treated patients with elevated triglycerides, or TG, and fully align with Amarin's commitment to addressing the burden of CV disease across the healthcare ecosystem. The updated guideline reinforces that patients on statin therapy can experience residual CV risk driven by elevated TG levels - a significant clinical challenge affecting millions of Americans. Amarin's VASCEPA/VAZKEPA, or icosapent ethyl, is an effective, safe, oral therapy that has been prescribed more than 30M times globally.
Amarin CFO Says Q4 Cash Flow Turned Positive Ahead of Schedule
Peter Fishman, Amarin's Chief Financial Officer, said, "Our fourth quarter performance reflects our early success in optimizing the Company's operations and creating what we believe is a more efficient platform for long-term growth. We realized $31 million of the expected $70 million in cost savings from our restructuring initiatives and have incurred nearly all of the $37 - $40 million in restructuring costs. Our cash position improved sequentially and year over year, ending 2025 with total cash and investments of $303 million and no debt. As a direct result of our continued revenue generation and new financial operating profile, our return to positive cash flow in the fourth quarter was ahead of schedule and has positioned us to generate positive cash flow for the full year ahead. We are well positioned to deliver on our operational and strategic priorities in 2026."
Amarin Reports Q4 Revenue of $49.2M, Down from $62.3M Last Year
Reports Q4 revenue $49.2M vs. $62.3M last year. "Our performance in the fourth quarter and full year of 2025 confirmed both the initial impact and long-term potential of our strategic initiatives and re-imagined operating model," said Aaron Berg, President and Chief Executive Officer of Amarin. "We have entered 2026 from an improved position of market, operational, and financial strength. We have maintained our U.S. leading market share for VASCEPA and are actively expanding our presence in Europe for VAZKEPA via our long-term partnership agreement with Recordati S.p.A., strengthening our now fully partnered international commercial strategy. We are a leaner organization, having made great progress in reducing costs and narrowing our losses, while continuing to invest in expanding an already formidable body of scientific knowledge that supports our global VASCEPA/VAZKEPA franchise and its proven ability to reduce cardiovascular risk. While work remains, we are encouraged by our progress and continue to examine strategic actions to maximize future shareholder value and options regarding management of capital."
Amarin Discusses Innovations in Triglyceride Therapies and VASCEPA Outlook
Amarin commented on recent innovations in therapies for patients with elevated triglycerides and shared its perspective on how these developments stand to shape patient access and treatment strategies. Specifically, new therapies for these patients are likely to expand the use of existing, proven options over time, including Amarin's VASCEPA/VAZKEPA. In addition, through its approved indication for severe hypertriglyceridemia, which is defined as TG greater than or equal to500 mg/dL, as well as strong clinical evidence, affordability, and broad reimbursement, VASCEPA/VAZKEPA aligns with current payor-driven step therapy programs, which require patients to try existing safe and efficacious treatment options before newer, more expensive sHTG alternatives.
Amarin Expects 2025 Net Revenue Between $212M and $217M
Amarin Corporation announced select preliminary unaudited 2025 financial highlights, provided a summary of key 2025 operational accomplishments, and outlined 2026 priorities in advance of business development and investor meetings in San Francisco during the week of January 12, 2026. Income Statement: Q4 2025 net revenue expected to range between $48 - $53 million and FY 2025 net revenue expected to range between $212 - $217 million. Realized approximately 50% of the $70 million in estimated OPEX savings related to the 2025 restructuring; on track to realize the full estimated savings benefit by June 30, 2026, resulting in a significantly lower operating cost structure going forward. Expected restructuring costs to range from $37 - $40 million, up from the prior estimate of $30 - $37 million.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.